Medtronic, Inc. (MDT) PT Lowered to $103 at Truist Securities

Truist Securities analyst Richard Newitter lowered the price target on Medtronic, Inc. (NYSE: MDT) to $103.00 (from $107.00) while maintaining a Hold rating.

The analyst commented, "MDT posted modest org. rev (+6% org vs 5.6% CNS) & EPS upside ($1.36 vs $1.31 CNS) + reiterated FY26 guidance. MDT saw relatively strong performance, beating CNS across 3 of 4 segments, with Diabetes (OUS strength) and Cardiovascular (EP/PFA strength) offsetting Neurosciences underperformance (Specialty Therapies Weakness). Mgmt. reit. its preliminary FY27 expectations for revenue growth acceleration and HSD EPS growth including the extra selling week in F1Q27. While we have 'warmed up' to the rev accel. thesis (narrative on MDT's side) w/ some real tangible drivers (CAS, RDN), but look for faster org. pick-up and/or better EPS grth & stay Hold; PT $103 (v $107)."

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Phillips 66, Marathon Merger Talks Collapsed - Semafor